BCR ABL1 MUTATION ANALYSIS

BCR‑ABL1 mutation analysis identifies mutations in the BCR‑ABL1 fusion gene—commonly in the kinase domain—that can cause resistance to tyrosine kinase inhibitors, using sensitive molecular testing performed on peripheral blood (or bone marrow when indicated). Results help hematologists personalize therapy for chronic myeloid leukemia (CML) and Philadelphia chromosome–positive ALL by detecting resistance mutations, guiding selection or adjustment of targeted treatments, and monitoring response. Touch Connect arranges trained phlebotomy for home sample collection across Dubai and the UAE with secure laboratory processing and clinician-ready reports to support timely treatment decisions within local care pathways.

• BCR‑ABL1 transcript level (International Scale %)
• BCR‑ABL1 transcript type (e13a2, e14a2, other variants)
• ABL1 kinase‑domain mutation panel (including T315I, Y253H, E255K/V, M351T, F317L, H396P)
• Mutation allele frequency (variant %)
• Method & sensitivity (qRT‑PCR / targeted NGS; limit of detection ≈1%)

• High‑sensitivity ABL1 kinase‑domain mutation detection (including clinically significant mutations such as T315I) for Philadelphia‑positive leukemias
• Actionable mutation report to guide tyrosine kinase inhibitor (TKI) selection and dose adjustments in CML and Ph+ ALL
• Next‑generation sequencing and targeted assays to identify low‑level resistant clones relevant to treatment planning
• Trained phlebotomist home blood collection across Dubai and the UAE with secure sample stabilization and chain‑of‑custody
• Secure, clinician‑ready digital report with timely turnaround and billing support in AED for UAE healthcare providers

• Detects ABL1 kinase‑domain mutations in BCR‑ABL1 positive patients to identify tyrosine kinase inhibitor (TKI) resistance
• High‑sensitivity molecular sequencing (validated methods) to identify both common and rare resistance variants
• Provides an actionable clinical report with mutation interpretation to support selection of imatinib, dasatinib, nilotinib, ponatinib or alternative therapies
• Peripheral blood home sample collection across Dubai and the UAE performed by trained phlebotomists for patient convenience
• Secure electronic results with rapid turnaround (typically within 3–7 business days) for prompt review by your hematologist or oncology team

• Detects BCR‑ABL1 ABL1 kinase‑domain mutations (including clinically significant variants such as T315I) to identify TKI resistance
• High‑sensitivity molecular sequencing for precise mutation identification to guide personalized leukemia therapy
• Suitable for baseline assessment and ongoing monitoring of CML and Ph‑positive leukemia patients on targeted treatment
• Convenient home sample collection across Dubai and the UAE with analysis in an accredited clinical laboratory and secure electronic reporting